F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study

Joint Bone Spine. 2015 Oct;82(5):381-3. doi: 10.1016/j.jbspin.2015.01.014. Epub 2015 Mar 13.
No abstract available

Keywords: Adalimumab; Positron emission tomography; Rheumatoid arthritis; Tumor necrosis factor antagonists.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use*
  • Adult
  • Aged
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / diagnostic imaging
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Positron-Emission Tomography / methods*
  • Prospective Studies
  • Radiopharmaceuticals
  • Time Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antirheumatic Agents
  • Radiopharmaceuticals
  • Tumor Necrosis Factor-alpha
  • Fluorodeoxyglucose F18
  • Adalimumab